Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 513Neoplasms 381Lymphoma 341Prostatic Neoplasms 291Melanoma 284Carcinoma, Non-Small-Cell Lung 278Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Lung Neoplasms 257Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma, Non-Hodgkin 227Colonic Neoplasms 226Ovarian Neoplasms 208Lymphoma, Large B-Cell, Diffuse 208Multiple Myeloma 207Brain Neoplasms 206Colorectal Neoplasms 203Lymphoma, Follicular 201Rectal Neoplasms 194Burkitt Lymphoma 183Neoplasm Metastasis 180Carcinoma, Renal Cell 172Glioblastoma 169Sarcoma 168Lymphoma, Mantle-Cell 166Pancreatic Neoplasms 158Lymphoma, B-Cell, Marginal Zone 145Unspecified Adult Solid Tumor, Protocol Specific 141Hodgkin Disease 141

Interventions

obeticholic acid 1Specimen Handling 1Erlotinib Hydrochloride 1Endoscopy, Gastrointestinal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Attenuated familial adenomatous polyposis × Clear all
NCT05223036 2026-05-14

Testing Obeticholic Acid for Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled
Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT02961374 2022-07-26

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Gastrointestinal

Attenuated familial adenomatous polyposis, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡